Login to Your Account

BIO 2012 International Convention

Ambrx Taking ADCs Beyond Cancer in $303M Merck Deal

By Jennifer Boggs
Managing Editor

Tuesday, June 19, 2012
BOSTON – Ambrx Inc. helped kick off the BIO International Convention Monday by disclosing a potential $303 million collaboration with Merck & Co. Inc. using its EuCODE platform to develop antibody-drug conjugates (ADCs) against oncology and other indications.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription